Literature DB >> 26456833

Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.

Sonia Mulero-Navarro1, Ana Sevilla2, Angel C Roman3, Dung-Fang Lee2, Sunita L D'Souza2, Sherly Pardo4, Ilan Riess5, Jie Su2, Ninette Cohen6, Christoph Schaniel7, Nelson A Rodriguez8, Alessia Baccarini6, Brian D Brown6, Hélène Cavé9, Aurélie Caye9, Marion Strullu9, Safak Yalcin10, Christopher Y Park10, Perundurai S Dhandapany8, Ge Yongchao11, Lisa Edelmann6, Sawsan Bahieg6, Patrick Raynal12, Elisabetta Flex13, Marco Tartaglia14, Kateri A Moore2, Ihor R Lemischka7, Bruce D Gelb15.   

Abstract

Somatic PTPN11 mutations cause juvenile myelomonocytic leukemia (JMML). Germline PTPN11 defects cause Noonan syndrome (NS), and specific inherited mutations cause NS/JMML. Here, we report that hematopoietic cells differentiated from human induced pluripotent stem cells (hiPSCs) harboring NS/JMML-causing PTPN11 mutations recapitulated JMML features. hiPSC-derived NS/JMML myeloid cells exhibited increased signaling through STAT5 and upregulation of miR-223 and miR-15a. Similarly, miR-223 and miR-15a were upregulated in 11/19 JMML bone marrow mononuclear cells harboring PTPN11 mutations, but not those without PTPN11 defects. Reducing miR-223's function in NS/JMML hiPSCs normalized myelogenesis. MicroRNA target gene expression levels were reduced in hiPSC-derived myeloid cells as well as in JMML cells with PTPN11 mutations. Thus, studying an inherited human cancer syndrome with hiPSCs illuminated early oncogenesis prior to the accumulation of secondary genomic alterations, enabling us to discover microRNA dysregulation, establishing a genotype-phenotype association for JMML and providing therapeutic targets.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26456833      PMCID: PMC4618050          DOI: 10.1016/j.celrep.2015.09.019

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  23 in total

1.  miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β.

Authors:  Wei Sun; Wenwen Shen; Shuang Yang; Fen Hu; Huihui Li; Tian-Hui Zhu
Journal:  Cell Res       Date:  2010-09-21       Impact factor: 25.617

2.  Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures.

Authors:  Marion Kennedy; Sunita L D'Souza; Macarena Lynch-Kattman; Staci Schwantz; Gordon Keller
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Authors:  M Golam Mohi; Ifor R Williams; Charles R Dearolf; Gordon Chan; Jeffery L Kutok; Sarah Cohen; Kelly Morgan; Christina Boulton; Hirokazu Shigematsu; Heike Keilhack; Koichi Akashi; D Gary Gilliland; Benjamin G Neel
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

4.  Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.

Authors:  B Pérez; F Mechinaud; C Galambrun; N Ben Romdhane; B Isidor; N Philip; J Derain-Court; B Cassinat; J Lachenaud; S Kaltenbach; A Salmon; C Désirée; S Pereira; M L Menot; N Royer; O Fenneteau; A Baruchel; C Chomienne; A Verloes; H Cavé
Journal:  J Med Genet       Date:  2010-06-12       Impact factor: 6.318

5.  Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Authors:  Shilpa Gandre-Babbe; Prasuna Paluru; Chiaka Aribeana; Stella T Chou; Silvia Bresolin; Lin Lu; Spencer K Sullivan; Sarah K Tasian; Julie Weng; Helene Favre; John K Choi; Deborah L French; Mignon L Loh; Mitchell J Weiss
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

Review 6.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

7.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

8.  High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries.

Authors:  Gavriel Mullokandov; Alessia Baccarini; Albert Ruzo; Anitha D Jayaprakash; Navpreet Tung; Benjamin Israelow; Matthew J Evans; Ravi Sachidanandam; Brian D Brown
Journal:  Nat Methods       Date:  2012-07-01       Impact factor: 28.547

9.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

10.  Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells.

Authors:  Andriana G Kotini; Chan-Jung Chang; Ibrahim Boussaad; Jeffrey J Delrow; Emily K Dolezal; Abhinav B Nagulapally; Fabiana Perna; Gregory A Fishbein; Virginia M Klimek; R David Hawkins; Danwei Huangfu; Charles E Murry; Timothy Graubert; Stephen D Nimer; Eirini P Papapetrou
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

View more
  33 in total

Review 1.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

2.  Patient-derived induced pluripotent stem cells in cancer research and precision oncology.

Authors:  Eirini P Papapetrou
Journal:  Nat Med       Date:  2016-12-06       Impact factor: 53.440

Review 3.  Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.

Authors:  Ryan C Smith; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2018-12-20       Impact factor: 24.633

Review 4.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

5.  Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.

Authors:  Ruoji Zhou; An Xu; Jian Tu; Mo Liu; Julian A Gingold; Ruiying Zhao; Dung-Fang Lee
Journal:  J Vis Exp       Date:  2018-06-13       Impact factor: 1.355

Review 6.  Modeling Leukemia with Human Induced Pluripotent Stem Cells.

Authors:  Eirini P Papapetrou
Journal:  Cold Spring Harb Perspect Med       Date:  2019-12-02       Impact factor: 6.915

Review 7.  Gene delivery methods and genome editing of human pluripotent stem cells.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Iga Kołodziejczak; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-18

Review 8.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

Review 9.  Cancer in a dish: progress using stem cells as a platform for cancer research.

Authors:  Mo Liu; Jian Tu; Julian A Gingold; Celine Shuet Lin Kong; Dung-Fang Lee
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

10.  Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells.

Authors:  L Charaf; F-X Mahon; I Lamrissi-Garcia; I Moranvillier; F Beliveau; B Cardinaud; S Dabernat; H de Verneuil; F Moreau-Gaudry; A Bedel
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.